Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
University of Hong Kong · Chinese University of Hong Kong · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
372
total citations
- FWCI
- 37.20
- Percentile
- 100%
- References
- 20
Citations per year
Authors
17Topics & keywords
Topics
Keywords
- Titer
- Virology
- Heterologous
- Neutralizing antibody
- Vaccination
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Antibody
- Virus
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- NRNational Research Foundation
- NNNational Natural Science Foundation of ChinaAwards: COVID-19, N_HKU737/18
- RGResearch Grants Council, University Grants CommitteeAward: T11-705/21-N
- IAInnovation and Technology Commission
- FAFood and Health BureauAward: COVID1903003 and COVID190126
- NINational Institutes of HealthAwards: COVID-19, AI151810
- HAHealth and Medical Research FundAwards: T11-705/21-N, COVID190126, COVID1903003 and COVID190126, COVID1903003